Evidence map›Paper›PMID 38864641›Full record

Observational studyMicrobiology spectrum2024

No improvement in mortality among critically ill patients with carbapenems as initial empirical therapy and more detection of multi-drug resistant pathogens associated with longer use: a post hoc analysis of a prospective cohort study.

Junki Ishii, Mitsuaki Nishikimi, Liesbet De Bus, Jan De Waele, Akihiro Takaba, Akira Kuriyama, Atsuko Kobayashi, Chie Tanaka, Hideki Hashi, Hideki Hashimoto and 19 more

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Junki IshiiDepartment of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID 0000-0001-9661-3693
Mitsuaki NishikimiDepartment of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Liesbet De BusDepartment of Intensive Care Medicine, Ghent University Hospital, Ghent, Belgium.
Jan De WaeleDepartment of Intensive Care Medicine, Ghent University Hospital, Ghent, Belgium.
Akihiro TakabaJA Hiroshima General Hospital, Hiroshima, Japan.
Akira KuriyamaEmergency and Critical Care Center, Kurashiki Central Hospital, Okayama, Japan.ORCID 0000-0002-6633-7816
Atsuko KobayashiTakarazuka City Hospital, Hyogo, Japan.
Chie TanakaNippon Medical School Tama Nagayama Hospital, Tokyo, Japan.
Hideki HashiTokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan.
Hideki HashimotoHitachi General Hospital, Ibaraki, Japan.
Hiroshi NashikiIwate Prefectural Central Hospital, Iwate, Japan.
Mami ShibataDepartment of Emergency and Critical Care Medicine, Wakayama Medical University Hospital, Wakayama, Japan.
Masafumi KanamotoDepartment of Anesthesiology, Gunma Prefectural Cardiovascular Center, , Gunma, Japan.
Masashi InoueDepartment of Anesthesiology, Nagoya City University Hospital, Aichi, Japan.
Satoru HashimotoNon-Profit Organization ICU Collaboration Network (ICON), Tokyo, Japan.
Shinshu KatayamaDivision of Intensive Care, Department of Anesthesiology and Intensive Care Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
Shinsuke FujiwaraNational Hospital Organization Ureshino Medical Center, Saga, Japan.
Shinya KamedaJikei University School of Medicine Hospital, Tokyo, Japan.
Shunsuke ShindoOmori Red Cross Hospital, Tokyo, Japan.
Tetsuya KomuroDepartment of General Internal Medicine, TMG Muneoka Central Hospital, Saitama, Japan.
Toshiomi KawagishiToyama University Hospital, Toyama, Japan.
Yasumasa KawanoFukuoka University Hospital, Fukuoka, Japan.
Yoshihito FujitaAichi Medical University Hospital, Aichi, Japan.
Yoshiko KidaDepartment of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Yuya HaraYodogawa Christian Hospital, Osaka, Japan.
Hideki YoshidaDepartment of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.
Shigeki FujitaniDepartment of Emergency and Critical Care Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.
Nobuaki ShimeDepartment of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
DIANA study Japanese group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Whether empirical therapy with carbapenems positively affects the outcomes of critically ill patients with bacterial infections remains unclear. This study aimed to investigate whether the use of carbapenems as the initial antimicrobial administration reduces mortality and whether the duration of carbapenem use affects the detection of multidrug-resistant (MDR) pathogens. This was a post hoc analysis of data acquired from Japanese participating sites from a multicenter, prospective observational study [Determinants of Antimicrobial Use and De-escalation in Critical Care (DIANA study)]. A total of 268 adult patients with clinically suspected or confirmed bacterial infections from 31 Japanese intensive care units (ICUs) were analyzed. The patients were divided into two groups: patients who were administered carbapenems as initial antimicrobials (initial carbapenem group,

Indexed as

Anti-Bacterial AgentsBacterial InfectionsCarbapenemsCritical IllnessDrug Resistance, Multiple, BacterialIntensive Care UnitsAgedAged, 80 and overBacteriaFemaleHumansJapanMaleMiddle AgedProspective StudiesAnti-Bacterial AgentsCarbapenemscarbapenemcritically illinfectious diseaseinitial empirical therapyintensive care unitmultidrug resistance

Identifiers

PMID38864641
PMCPMC11218456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.